Trial Profile
Phase II Trial of Combined Modality Therapy With Growth Factor Support in Locally Advanced NSCLC.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Docetaxel (Primary) ; Etoposide (Primary) ; Filgrastim (Primary) ; Pegfilgrastim (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 19 Apr 2012 Actual end date (Jan 2010) added as reported by ClinicalTrials.gov.
- 19 Apr 2012 Actual patient number is 26 according to ClinicalTrials.gov.
- 19 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.